Eptifibatide (Eptifibatide)

Trade Name : Eptifibatide

Amneal Biosciences

INJECTION

Strength 2 mg/mL

EPTIFIBATIDE Decreased Platelet Aggregation [PE],Platelet Aggregation Inhibitor [EPC]

Delivery Process

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

We’ll Get in Touch

Once we review your request, we’ll send you an estimated price for the medicine within 2-5 days.

Confirmation and Payment

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Product information is meant for

Wholesalers Suppliers Exporters Doctors MOH Tender Supplies Hospitals Brand CROs Comparator Supplies Generic Cooperate Sourcing Individual Patients Indian Institutional Buyers

Disclaimer

Trade Marks displayed in compliance with provisions of: Trademark Act, 1999 u/s 30 and 30 (1) of "Fair use"

GNH India is WHO GDP and ISO 9001 2015 Certified Pharmaceutical Wholesaler/ Supplier/ Exporters/ Importer from India of Eptifibatide (Eptifibatide) which is also known as Eptifibatide and Manufactured by Amneal Biosciences. It is available in strength of 2 mg/mL per ml. Read more

Eptifibatide (Eptifibatide) is supplied for Tenders/ Emergency imports/ Un - licensed, Specials, Orphan drug/ Name patient line/ RLD supplies/ Reference listed drugs/ Comparator Drug/ Bio-Similar/ Innovator samples For Clinical trials.  Click to know price.     Read less

Packaging and Delivery

Validated Cold Chain Shipment

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Inquire directly from our website and get 5% off on any medicine!

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Read more

About GNH

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Read more
  • No data
  • Eptifibatide injection is a platelet aggregation inhibitor indicated for:
  • Treatment of acute coronary syndrome (ACS) managed medically or with percutaneous coronary intervention (PCI) n
  • Treatment of patients undergoing PCI (including intracoronary stenting) n
  • Before infusion of eptifibatide injection, the following laboratory tests should be performed to identify pre-existing hemostatic abnormalities: hematocrit or hemoglobin, platelet count, serum creatinine and PT/aPTT. In patients undergoing PCI, the activated clotting time (ACT) should also be measured.
  • The activated partial thromboplastin time (aPTT) should be maintained between 50 and 70 seconds unless PCI is to be performed. In patients treated with heparin, bleeding can be minimized by close monitoring of the aPTT and ACT.
  • ACS or PCI: 180 mcg/kg IV bolus as soon as possible after diagnosis followed by infusion at 2 mcg/kg/min.u00a0u00a0n
  • PCI: Add a second 180 mcg/kg bolus at 10 minutes. n
  • In patients with creatinine clearance <50 mL/min, reduce the infusion to 1 mcg/kg/min.u00a0u00a0n
  • No data
  • 20 mg/10 mL (2 mg/mL) in a single-dose vial for bolus injection n
  • 75 mg/100 mL (0.75 mg/mL) in a single-dose vial for infusion n
  • Treatment with eptifibatide is contraindicated in patients with:
  • Bleeding diathesis or bleeding within the previous 30 days n
  • Severe uncontrolled hypertension n
  • Major surgery within the preceding 6 weeks n
  • Stroke within 30 days or any history of hemorrhagic stroke n
  • Coadministration of another parenteral GP IIb/IIIa inhibitor n
  • Dependency on renal dialysis n
  • Known hypersensitivity to any component of the product n
  • No data
  • Eptifibatide can cause serious bleeding. If bleeding cannot be controlled, discontinue eptifibatide immediately. Minimize vascular and other traumas. If heparin is given concomitantly, monitor aPTT or ACT. n
  • Thrombocytopenia: Discontinue eptifibatide and heparin. Monitor and treat condition appropriately. n
  • The following serious adverse reaction is also discussed elsewhere in the labeling:
  • Bleeding and hypotension are the most commonly reported adverse reactions. n
  • To report SUSPECTED ADVERSE REACTIONS, contact Amneal at 1-855-266-3251 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
  • Coadministration of antiplatelet agents, thrombolytics, heparin, aspirin and chronic NSAID use increases the risk of bleeding. Concomitant treatment with other inhibitors of platelet receptor GP IIb/IIIa should be avoided.
  • Coadministration of antiplatelet agents, thrombolytics, heparin, aspirin and chronic NSAID use increases the risk of bleeding. Avoid concomitant use with other glycoprotein (GP) IIb/IIIa inhibitors. n
  • No data
  • Geriatric Use:
  • (8.5)
  • There has been only limited experience with overdosage of eptifibatide. There were 8 patients in the IMPACT II study, 9 patients in the PURSUIT study and no patients in the ESPRIT study who received bolus doses and/or infusion doses more than double those called for in the protocols. None of these patients experienced an intracranial bleed or other major bleeding.
  • Eptifibatide was not lethal to rats, rabbits, or monkeys when administered by continuous intravenous infusion for 90 minutes at a total dose of 45 mg/kg (about 2 to 5 times the recommended maximum daily human dose on a body surface area basis). Symptoms of acute toxicity were loss of righting reflex, dyspnea, ptosis and decreased muscle tone in rabbits and petechial hemorrhages in the femoral and abdominal areas of monkeys.
  • From studies, eptifibatide is not extensively bound to plasma proteins and thus may be cleared from plasma by dialysis.
  • Eptifibatide is a cyclic heptapeptide containing 6 amino acids and 1 mercaptopropionyl (des-amino cysteinyl) residue. An interchain disulfide bridge is formed between the cysteine amide and the mercaptopropionyl moieties. Chemically it is N-(aminoiminomethyl)-N-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-u03b1-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic (1u21926)-disulfide. Eptifibatide binds to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets and inhibits platelet aggregation.
  • The eptifibatide peptide is produced by solution-phase peptide synthesis, and is purified by preparative reverse-phase liquid chromatography and lyophilized. The structural formula is:
  • Eptifibatide injection is a clear, colorless, sterile, non-pyrogenic solution for intravenous (IV) use with an empirical formula of CHNOS and a molecular weight of 831.96. Each 10-mL vial contains 2 mg/mL of eptifibatide and each 100-mL vial contains 0.75 mg/mL of eptifibatide. Each vial of either size also contains 5.25 mg/mL citric acid in water for injection and sodium hydroxide to adjust the pH to 5.35.
  • No data
  • No long-term studies in animals have been performed to evaluate the carcinogenic potential of eptifibatide. Eptifibatide was not genotoxic in the Ames test, the mouse lymphoma cell (L 5178Y, TK+/-) forward mutation test, the human lymphocyte chromosome aberration test, or the mouse micronucleus test. Administered by continuous intravenous infusion at total daily doses up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis), eptifibatide had no effect on fertility and reproductive performance of male and female rats.
  • Eptifibatide was studied in 3 placebo-controlled, randomized studies. PURSUIT evaluated patients with acute coronary syndromes: UA or NSTEMI. Two other studies, ESPRIT and IMPACT II, evaluated patients about to undergo a PCI. Patients underwent primarily balloon angioplasty in IMPACT II and intracoronary stent placement, with or without angioplasty, in ESPRIT.
  • No data
  • Instruct patients to inform the doctor or healthcare provider about any medical conditions, medications and allergies.
  • Manufactured by:n Hyderabad-500 043, INDIA
  • Distributed by:n Bridgewater, NJ 08807
  • Rev. 06-2016-00
  • LEA-019755-00
  • No data

Browse Our Services And Processes

Comparator Sourcing for Clinical Trials

Comparator Sourcing for Clinical Trials

GNH India brings over 10 years of experience in Comparator

Read More

Name Patient Supply

Name Patient Supply

Today, the exact cause for many rare diseases remains unknown

Read More

Validated Cold Chain Shipment

Validated Cold Chain Shipment

With shifting of pharma industry from synthetic molecules to biologic

Read More

Clinical Trials Supply

Clinical Trials Supply

STOP SOURCING..... START SMART SOURCING...... COME STRAIGHT TO THE SOURCE

Read More

Dossiers and Stability Studies

Dossiers and Stability Studies

STABILITY STUDIES STABILITY, BA / BE STUDIES Due to our active

Read More

Pharmaceutical Contract Manufacturing

Pharmaceutical Contract Manufacturing

GNH Provides Contract Manufacturing services for: Generic Medicines with following

Read More

Pricing

Pricing

PRICING POLICY Terms of sales are typically prepaid, unless otherwise

Read More

Disclaimer

Please see the Legal Notice for detailed terms and disclaimers. The Legal Notice governs the use of this Website and by accessing and using this Website you agree to be bound by and accept the Legal Notice.

Browse from other international pharmaceuticals

General

64020 Products

GNH India Brings to over 64036 Product SKUs from India all at 1 place with easy access and global deliveries.

US NDC

71247 Products

GNH India Brings to over 71252 Product SKUs from India all at 1 place with easy access and global deliveries.

Canadian DIN

51046 Products

GNH India Brings to over 51047 Product SKUs from India all at 1 place with easy access and global deliveries.

Swiss Drugs

150 Products

GNH India Brings to over 150 Product SKUs from India all at 1 place with easy access and global deliveries.

NZ Drugs

13296 Products

GNH Brings to over 13298 Product SKUs from India all at 1 place with easy access and global deliveries.

FAQ

Check out our delivery process

Can’t find what
you’re looking for?

Contact US
Pharmexcil
DB
FIEO-2016
SiteLock

Copyright © 2024 GNHIndia .com. All Rights Reserved. Please read Legal Notice for further details.

Disclaimer: Product names, logos, brands and other trademarks featured or referred to are the property of their respective trademark holders.